Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 194

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 194
---
 shares. Proposed Treasury Regulations, the preamble to which state that they can be relied upon until final Treasury Regulations are issued, exempt from FATCA withholding gross proceeds from the dispositions of stock. To prevent withholding on dividends, Non-U.S. Holders may be required to provide the Company (or its withholding agents) with applicable tax forms or other information. Non-U.S. Holders are urged to consult with their own tax advisors regarding the effect, if any, of FATCA to them based on their particular circumstances.

<div align='center'>134

PLAN OF DISTRIBUTION</div>

Maxim Group LLC has agreed to act as our lead placement agent in connection with this offering on a reasonable best efforts basis subject to the terms and conditions of the placement agency agreement dated May 29, 2025. The placement agent is not purchasing or selling any of the securities offered by this prospectus, nor is it required to arrange for the purchase and sale of any specific number or dollar amount of such securities, other than to use its reasonable “best efforts” to arrange for the sale of such securities by us. Therefore, we may not sell all of the securities being offered pursuant to this prospectus. The securities will be offered at a fixed price and are expected to be issued in a single closing. We will enter into a securities purchase agreement directly with certain investors, at the investor’s option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. The placement agent may engage one or more subagents or selected dealers in connection with this offering.

We are offering on a “best efforts” basis up to 2,260,000 Units, each consisting of one common share and one warrant.

Each warrant will be exercisable for one common share. The exercise price of each warrant is $3.10. The warrants will be immediately exercisable (subject to the beneficial ownership cap) and may be exercised until the fifth anniversary of the date of issuance.

The following table shows the public offering price, placement agent fees and proceeds, before expenses, to us.

|                                 |     |     Per 
    Unit |
| Public offering price           |     | $3.1000 |
| Placement agent fees            |     | $0.2325 |
| Proceeds to us, before expenses |     | $2.8675 |

We estimate that the total expenses of the offering, including registration, filing and listing fees